Abstract

INTRODUCTION

Pazopanib acts as a multitargeted tyrosine kinase inhibitor. It has been shown to be effective in patients with advanced stage Soft Tissue Sarcomas (STSs). We aimed to evaluate survival times and significant side effects by making a retrospective evaluation of real-life data.

METHODS

This study was carried out with a retrospective method. Clinical characteristics of adult patients with advanced STSs treated with the pazopanib were recorded in the hospital's patient registry database. Patients without medical records were excluded from the study. Objective response rate (ORR), Progression-free survival (PFS), overall survival (OS), and treatment-related pneumothorax and hypertension side effects were determined.

RESULTS

Forty adult patients were included (males: 55%). The median age was 44.5 years (range: 20-88). Malignant mesenchymal tumor by histopathology was found in 32.5% of the sample. Eighty-eight percent of the sample had a Stage 3 or higher disease at the time of initial diagnosis. Seventy percent of the patients had lung metastases. Seventy percent of the patients received two or more lines of systemic chemotherapy prior to pazopanib. The ORR to the pazopanib was 45% for whole patients. PFS (IQR) was determined as 5.73 (2.67) months. OS (IQR) was 8.54 (17.81) months. Pneumothorax was detected during pazopanib in twelve and a half percent of patients. Hypertension was detected during pazopanib in fifteen percent of patients.

DISCUSSION AND CONCLUSION

Pazopanib led to significant survival in this pretreated population of patients based on real-life data. It also has a manageable side-effect profile.